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COULD BIOBANKING BE A MEANS TO INCLUDE
"HEALTH CARE HAVE-NOTS" IN THE GENOMICS
REVOLUTION?
Michael J. Malinowski *
INTRODUCTION
The United States invests tens of billions of taxpayer dollars in basic
research annually,1 while clinical research is financed largely by the
commercial sector and with a focus on market consumption of resulting
products. 2  Populations without economic means or a loud political
voice traditionally have been marginalized in clinical research,
including children, 3 women, 4 and many minority groups.5  For the
* J.D. Yale Law School 1991; B.A., summa cum laude, Tufts University 1987. Ernest
R. and Iris M. Eldred Endowed Professor of Law, Paul M. Hebert Law Center,
Louisiana State University (LSU), and Co-Founder and Associate Director, Program
in Law, Science, and Public Health. The author would like to thank Daven Williams
and Reginald Tucker for their valued research assistance.
' Investment through NIH alone was $28 billion in 2004, and $28.6 billion has been
budgeted for 2005. Jonathan Weisman, 2006 Cuts in Domestic Spending on Table,
WASH. POST, May 27, 2004, at Al; Drug Development: Medicine Price Hike
Highlights Controversy of Government Funding Drug Research, HEALTH & MED.
WK., June 14, 2004, at 325.
2 See generally PHRMA, PHARMACEUTICAL INDUSTRY PROFILE 2005 (2005)
[hereinafter PHRMA], available at
http://www.phrma.org/publications/publications//2005-03-17.1143.pdf. Gordon
Duval, Institutional Conflicts of Interest: Protecting Human Subjects, Scientific
Integrity, and Institutional Accountability, 32 J.L. MED & ETHICS 613 (2004);
Thomas Bodenheimer, Uneasy Alliance-Clinical Investigators and the
Pharmaceutical Industry, 342 NEW ENG. J. MED. 1539 (2000).
3 The U.S. Government has introduced an incentive, a quid pro quo, to inspire
pharmaceutical companies to gather clinical data on the impact of their products on
children through the pediatric exclusivity. Janet Fricker, Too Much Too Young, NEW
SCIENTIST, Feb. 20, 1999, at 18. Pharmaceutical sponsors are granted patent
extensions in exchange for compiling this data. See id. A dearth of pediatric clinical
data for pharmaceuticals routinely prescribed to children inspired this reform. See id.
See also Jennifer Powell, Law, Docs Eye Safer Drugs for Kids, BOSTON HERALD,
June 10, 2001, at 27.
4 See generally NIH, Office of Extramural Research, NIH Policy and Guidelines on
the Inclusion of Women and Minorities as Subjects in Clinical Research, available at
http://grants.nih.gov/grants/funding/women_min/guidelines-amended102001.htm.
Supportive data is available via the Office on Women's Health, Department of Health
and Human Services, http://www.4woman.gov/owh/ and the "Women's Health"
pages of the National Institutes of Health Internet site,
http://health.nih.gov/search.asp/28.
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purposes of this article, these groups will be referred to as "Health Care
Have-Nots" ("HCHNs"). Some of the HCHNs have been exploited in
clinical research studies, including studies sponsored and even directly
conducted by the U.S. government. 6  The Food and Drug
Administration ("FDA") has routinely approved and overseen human
clinical trials performed without demographic representation from the
HCHNs and, subsequently, authorized the market entry of resulting
products as treatments for diseases prevalent in the general population
and among HCHNs.7
5 See generally, AHRQ's Role in Eliminating Racial and Ethnic Disparities in Health
Before the Subcommittee on Criminal Justice, Drug Policy, and Human Resources,
107th Cong. ( May 21, 2002) (statement of Dr. Carolyn Clancy, Acting Director,
AHRQ), available at http://www.hhs.gov/as/testify/t020521.htm1. See generally
INSTITUTE OF MEDICINE, UNEQUAL TREATMENT: CONFRONTING RACIAL AND ETHNIC
DISPARITIES IN HEALTHCARE (Brain D. Smedley et al. eds., 2003), available at
http://www.iom.edu/report.asp?id=4475 [hereinafter UNEQUAL TREATMENT];
AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ), STRATEGIES FOR
IMPROVING MINORITY HEALTHCARE QUALITY (2004), available at
http://www.ahrq.gov/downloads/pub/evidence/pdf/minqual/minqual.pdf
(last visited Sept. 23, 2005) [hereinafter AHRQ REPORT]; AHRQ, Fact Sheet:
Addressing Racial and Ethnic Disparities in Health Care, available at
http://www.ahrq.gov/research/disparit.htm [hereinafter Fact Sheet]. The IOM Report
findings are damning:
The report says a large body of research underscores the existence of
disparities. For example, minorities are less likely to be given
appropriate cardiac medications or to undergo bypass surgery, and are
less likely to receive kidney dialysis or transplants. By contrast, they
are more likely to receive certain less-desirable procedures, such as
lower limb amputations for diabetes and other conditions.
Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care,
Institute of Medicine, http://www.iom.edu/?id=15962 (last visited Jan. 14, 2006).
6 Most notable is the Tuskegee syphilis project funded by the Public Health Service
over three decades. See generally Nancy Jecker, Tuskegee's Truths: Rethinking the
Tuskegee Syphilis Study, 343 NEW ENG J. MED. 1581 (2000); Patricia A. King,
Reflections on Race and Bioethics in the United States, 14 HEALTH MATRIX 149
(2004); Barbara L. Bemier, Class, Race and Poverty: Medical Technologies and
Sociopolitical Choices, 11 HARv. BLACKLETTER L. J. 115, 122-125 (1994).
7 This observation is representative of the U.S.'s free market system, which has
proven to be extremely productive. See generally PHRMA, supra note 2. Drug
sponsors are allotted free-market discretion, and, subsequent to approval of their
products, physicians are allotted discretion to prescribe off-label. "In fact, Congress
recognized the realities of off-label prescribing when it authorized Medicaid
reimbursement of pharmaceuticals for uses that appear in certain medical compendia,
even if the FDA has not approved that use for inclusion in labeling." See Lars Noah,
Informed Consent and the Elusive Dichotomy Between Standard and Experimental
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Contemporary biomedical research and development ("R&D")
in the U.S. is centering on the genomics revolution-an initiative to
understand gene and protein function as a means to intervene in the
biological pathways of disease and medical treatment, and to develop
more effective human health therapies. 8 Thus far, genomics has been
adding dimensions of precision to human health care product
development, fractioning traditional disease groups and markets, 9 and
raising health care costs.' 0  Bioinformatics, the combination of
information technology and biology, is the primary means to make
medical sense out of the map of the human genome, and
bioinformatics capabilities continue to expand." Consequentially, the
demand for access to human biological samples and medical
information never has been greater, and this demand has given rise to
ambitious biobanking initiatives-efforts to compile organized
collections of DNA samples and accompanying medical information
from human populations.
Therapy, 28 AMER. J. L. AND MED. 361, 398 (2002) (citing 42 U.S.C. §§ 1396r-
8(k)(6), 1395x(t)(2)(B) (2000)) (authorizing Medicare reimbursement for off-label
uses of oncology drugs if consistent with medical compendia or the peer-reviewed
literature).
8 See generally Symposium, The Genomics Revolution? Science, Law, and Policy, 66
LA. L. REV. 1 (2006) [hereinafter Genomics Revolution] (live conference transcripts
on file with author).
9 Michael J. Malinowski, Taking Genomics to the BioBank: Access to Human
Biological Samples and Medical Information, 66 LA. L. REV. 43, 46 n. 15 (2006).
'0 Given the precision introduced by genomics, smaller groups will have to shoulder
resulting R&D drug costs. See generally Jeffrey L. Moe, Commercialization
Considerations for Individualized Diagnostic and Drug Therapies Resulting from
Pharmacogenomics, 66 LA. L. REV. 103 (2005). This trend is likely to continue until
technology evolves to enable actual elimination of diseases rather than turning them
into chronically treated conditions. Michael McGinnis, Trends in Population Health-
are they influenced by medical and scientific advances? 66 LA. L. REV. 9, 19-20
(2006).
" See generally Genomics Revolution, supra note 8; POPULATIONS AND GENETICS:
LEGAL AND SocIo-ETHICAL PERSPECTIVES (Bartha Maria Knoppers ed., 2003); Lars
Noah, The Coming Pharmacogenomics Revolution: Tailoring Drugs to Fit Patients'
Genetic Profiles, 43 JURIMETRICS 1, 4-11 (2002); Michael J. Malinowski, Law,
Policy, and Market Implications of Genetic Profiling in Drug Development, 2
HOUSTON J. HEALTH L. & POL'Y 231 (2003); PHRMA, supra note 2. Bioinformatics
is the integration of biology and information technology to identify gene and protein
structure and function, usually with the ultimate objective of discovering drug targets.
See D.E. Winickoff, Governing Population Genomics: Law, Bioethics, and
Biopolitics in Three Case Studies, 43 JURIMETRICS 187, 189 (2003).
12 Biobanking is an extension of the practice for more than a century of collecting
human biological materials and building repositories for research use. See generally
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This article will explore the extent to which groups left out of
the genomics revolution could gain access through biobanking. 1 The
premise is that groups seeking access to the forefront of biomedical
R&D might draw upon case studies and the technology transfer
experiences of universities during the 1990s. This was a period of
transition from historic division between academia and industry to
intense integration of interests and collaborations among academia,
industry, and government to advance commercial biotechnology. 14 The
primary objective of this article is to probe the implications of active
biobanking by HCHNs.
Part I of this article will present an overview of the state of
healthcare finance in the U.S. and the realities of unequal health care
access and treatment. The HCHNs will be identified, and the message
is twofold. First, the costs of health care in the U.S. are rising and
shifting, causing more people to be uninsured and underinsured.' 5
Second, this trend threatens to exacerbate significant existing
inequalities in access to health care based upon race and ethnicity.'
6
Part I also will summarize the U.S. legacy of first exploitation and then
relative exclusion of HCHNs in biomedical R&D.
ALLEN BUCHANAN, An Ethical Framework for Biological Samples Policy, in
NATIONAL BIOETHICS ADVISORY COMMISSION, RESEARCH INVOLVING HUMAN
BIOLOGICAL MATERIALS: ETHICAL ISSUES AND POLICY GUIDANCE, VOLUME II
COMMISSIONED PAPERS, at B-I (2000) [hereinafter NBAC COMMISSIONED PAPERS],
available at http://www.georgetown.edu/research/nrcbl/nbac/hbmll.pdf; Elisa
Eiseman, Stored Tissue Samples: An Inventory of Sources in the United States, in
NBAC COMMISSIONED PAPERS, supra, at D-1; David Korn, Contribution of the
Human Tissue Archive to the Advancement of Medical Knowledge and the Public
Health, in NBAC COMMISSIONED PAPERS, supra, at E-1. See Symposium, Regulation
of Biobanks, 33 J. L. MED. & ETHICS 1 (Mark Rothstein & Bartha Knoppers eds.,
2005) [hereinafter Biobanks] (providing an excellent, timely treatment of
biobanking).
13 This article builds upon two collaborations with Professor Bartha Knoppers that
involved written symposia. See generally Genomics Revolution, supra note 8;
Biobanks, supra note 12.
14 See Michael J. Malinowski, Technology Transfer and Development Agreements, in
BIOTECHNOLOGY: LAW, BUSINESS, AND REGULATION § 3.02[C] (1999). See
generally Michael J. Malinowski, Institutional Conflicts and Responsibilities in an
Age ofAcademic-Industry Alliances, 8 WIDENER L. SYMP. J. 47 (2001).
15 Emily Friedman, Health Insurance, the Uninsured and Hospitals: Collision
Course, FRONTIERS HEALTH SERVICES MGMT., July 1, 2005, at 3; Thomas
Bodenheimer, High and Rising Health Care Costs, 142 ANNALS OF INTERNAL MED.
847 (2005).
16 See supra notes 5, 25-34 and accompanying text.
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Part II will shift focus to the present and future of biomedical
R&D, which is centering on population genetics and biobanking. This
discussion will introduce case studies that illustrate how some HCHNs
are gaining access to the forefront of the genomics revolution through
technology transfer and development in biobanking. Part II will
introduce proposals to increase biobanking by HCHNs as a means to
widen their access to both participation in genomics research and the
resulting health care innovations. This discussion also will directly
address the consequential implications of encouraging race-based
research and medicine. The article concludes that biobanking presents
an opportunity to increase positive participation of HCHNs in the
genomics revolution and encourages embracing that opportunity, but
with caution given the U.S. legacy of race-based medicine and research
and the lingering presence of that legacy as documented by the 1OM
and the AHQR. 17
I. THE HCHNS IN U.S. HEALTH CARE AND
BIOMEDICAL R&D
The state of health care finance in the U.S. is infamous and worsening:
forty-five million people are uninsured, most of them working, and
many millions more are underinsured;' 8 costs are rising significantly
and shifting from employers to employees; 19 a $62 trillion shortfall is
projected for Medicare, due largely to the new prescription drug
benefit; 20 states are slashing programs to offset their shortfalls; 21 the
Bush Administration is granting Medicare program waivers almost
17 See supra notes 5, 25-34 and accompanying text.
18 Shannon S. Venable, A Call to Action: Georgia Must Adopt New Standard of Care,
Licensure, Reimbursement and Privacy Laws for Telemedicine, 54 EMORY L.J. 1183,
1183-1184 (2005).
'9 Anne D'Innocenizo, Health Care Costs Continue to Shift, CHARLOTTE OBSERVER,
Sept. 14, 2005, at 3D; Glen Singer, Survey Shows Employers Will Shift Burden of
Health Benefits Increase, SUN-SENTINEL, Aug. 27, 2004; Anne D'Innocenizo,
Employers Shift Health Costs-Workers Will Take Larger Share in 2006, COM.
APPEAL, Sept. 14, 2005, at A3; Study Shows Impact of 6 Years of Double-Digit
Medical Rate Increases, MANAGED CARE WKLY. DIGEST, Mar. 28, 2005, at 103.
20 Alan Fram, Deficit Could Hit Record $477B, CINCINNATI POST, Jan. 26, 2004, at
A2; Robert Pear and Edmund L. Andrews, White House Says Congressional Estimate
of New Medicare Was Too Low, N.Y. TIMES, Feb. 2, 2004, at A14; Staggering Hidden
Costs of Medicare Prescriptions, NEW AMERICAN, Feb. 23, 2004, at 9; The Medicare
Alarm, ALBANY TIMES UNION, Apr. 5, 2004, at A6.
21 See Recipients Brace for Medicaid Co-Payments, CINCINNATI POST, June 27,
2005, at K5 (no author identified).
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carte blanche to accommodate the same; 22 and the Administration has
proposed cutting $60 billion (two percent) from Medicaid over the next
23 24decade. The situation is disparately worse for minority groups.
Both the Institutes of Medicine ("IOM") 25 and the Agency for
Healthcare Research and Quality ("AHRQ") at the Department of
Health and Human Services ("DHHS") have documented that minority
groups in the U.S. have significantly less access to health care, and the
26care they receive is of much lower quality. Minority groups get less
according to forty percent of access measures and more than sixty
percent of quality measures, and only one-fifth of this disparity is
27
attributable to a decline in insurance coverage. AHRQ has
determined that "Race and ethnicity influence a patient's chance of
receiving many specific procedures and treatments.', 28  Illustrations
include:
* "Heart disease. African Americans are 13 percent less
likely to undergo coronary angioplasty and one-third less
likely to undergo bypass surgery than are whites.,
29
* "Asthma. Among preschool children hospitalized for
asthma, only 7 percent of African American children ....
compared with 21 percent of white children, are prescribed
routine medications to prevent future asthma-related
hospitalizations."3
0
" "Breast cancer. The length of time between an abnormal
screening mammogram and the follow-up diagnostic test to
determine whether a woman has breast cancer is more than
22 id.
23 Josh Goldstein, U.S. Medicaid Cutbacks Would Hurt States Twice, PHIL. INQUIRER,
Feb. 8, 2005, at Cl; How Bush's Budget Goes Wrong, Bus. WK., Feb. 28, 2005, at
112; Robert Pear, Governors Prepare to Fight Medicaid Cuts, N.Y. TIMES, Feb. 27,
2005, at 27.
24 See generally Barbara A. Noah, The Participation of Underrepresented Minorities
in Clinical Research, 29 AM. J.L. & MED. 221 (2003); Barbara A. Noah, Racial
Disparities in the Delivery of Health Care, 35 SAN DIEGO L. REv. 135 (1998);
Barbara A. Noah, Racist Health Care?, 48 FLA. L. REv. 357 (1996).
25 See generally UNEQUAL TREATMENT, supra note 5.
26 See AHRQ Report, supra note 5; Fact Sheet, supra note 5.
27 See Fact Sheet, supra note 5.
28 See id. (emphasis added).
29 Id. (emphasis added).
30 Id. (emphasis added).
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twice as long in Asian American, black, and Hispanic
women as in white women."
3
'
* "Human immunodeficiency virus (HIV) infection. African
Americans with HIV infection are less likely to be on
antiretroviral therapy, less likely to receive prophylaxis for
Pneumocystis pneumonia, and less likely to be receiving
protease inhibitors than other persons with HIV."
32
* "Nursing home care. African American residents of nursing
homes are all far less likely than white residents to have
sensory and communication aids, such as glasses and
hearing aids."
' 33
Exclusion of minority groups is an overarching theme in the U.S.'s
biomedical research legacy. Exploitation is a second major theme. The
latter is synonymous with the Tuskegee study, 34  a Public Health
Service study which spanned four decades and traced the course of
untreated syphilis in African American males:
Initiated in 1932, the research targeted poor African-
American sharecroppers suffering from syphilis, but was
presented to subjects as a study of "bad blood." The study
continued until a July 26, 1972 New York Times story,
"Syphilis Victims in U.S. Study Went Untreated for 40
Years" exposed it as "the longest non-therapeutic
experiment on human beings in medical history."
35
The study, which confirmed the apprehensions of African Americans
and other minorities about participating in biomedical research and
compelled an apology from the United States government under the
31 Id. (emphasis added).
32 Fact Sheet, supra note 5 (emphasis added).
33 Id. (emphasis added).
34 See supra note 6; Dorothy E. Roberts, The Nature of Blacks' Skepticism About
Genetic Testing, 27 SETON HALL L. REV 971, 974 (1997). See generally JAMES H.
JONES, BAD BLOOD, THE TUSKEGEE SYPHILIS EXPERIMENT (1993).
35 PRICEWATERHOUSECOOPERS LLP, INSTITUTIONAL REVIEW BOARD (IRB)
REFERENCE BOOK 12 (Michele K. Russell-Einhom & Thomas Puglisi eds., 2001)
[hereinafter IRB REFERENCE BOOK].
2005]
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Clinton Administration, 36 encompassed 600 men, 399 with latent
syphilis and a control group of 201 without the disease. 37 These men
were "encouraged" to participate through free meals, medical
examinations, and burial insurance. 38 "In a reprehensible breach of
ethics, investigators took specific steps to ensure that subjects were
denied access to effective treatment, even after penicillin became
widely available, to preserve the integrity of the research. ,
39
Discrimination is a third major theme in the U.S.'s history of
treatment of minorities in medicine and biomedical R&D. A notable
and often-referenced example are the 1970s screening programs for
sickle cell trait which resulted in employment and insurance
discrimination against African Americans and restrictions on their
reproductive decision-making.4 °
The absence of just representation of minority groups in
biomedical research and the delivery of health care has been
acknowledged by the United States Government and inspired corrective
measures. These measures include the establishment and ongoing work
of the AHRQ.41
H. A PROPOSAL TO BIOBANK TO WIDEN ACCESS
FOR HCHNS
Population genetics is a means to engage in genomics and proteomics,
the understanding of gene and protein function, respectively.
42
Genomics occupies a central position in biomedical R&D, and there is
reason to believe that genomics will hold that position well into the
foreseeable future.43 Bioinformatics capabilities have made it possible
to extract extraordinary amounts of information from any given sample,
and to process voluminous amounts of information from large numbers
See id. "Finally, on May 6, 1997, nearly 20 years after the New York Times expose
[sic] and 65 years after the Syphilis Study began, surviving subjects and the members
of the Tuskegee Study Legacy Committee gathered at the White House to witness a
long-awaited apology from President Clinton on behalf of the United States
Government." Id. at 13. See generally Jones, supra note 34.3 7 Id. at 13 (emphasis added).
38id.
39 1d. at 12-13.
40 See generally Mark R. Farfel & Neil A. Holtzmann, Education, Consent and
Counseling in Sickle-Cell Screening Programs: Report of a Survey, 74 AM. J. PUB.
HEALTH 373 (1984).
41 See Agency for Healthcare Research and Quality (AHRQ), http://www.ahrq.gov.
42 See generally Genomics Revolution, supra note 8.
43 See generally id.
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of samples.44 These capabilities, which continue to expand by
multiples, are heightening demand for access to samples and
accompanying medical information.45  The combination of
bioinformatics capabilities and biobanks could prove a primary means
to make medical sense out of the map of the human genome.46
Some HCHNs already are gaining access to the forefront of the
genomics revolution through technology transfer and development
arrangements to engage in biobanking. Two of the more relevant case
studies are biobanking initiatives by PXE International ("PXE") and
Howard University ("Howard").47 PXE is a nonprofit foundation
established to use biobanking to encourage researchers to study and
develop therapies for pseudoxanthoma elasticum, a very rare hereditary
48connective tissue disorder that afflicts skin and eyes. Although PXE
has adopted an aggressive IP retention policy, 49 its biobank still has
attracted a number of laboratories globally. 50 As a case study, PXE
illustrates that, though we live in an age of academia-industry
integration, scientific accomplishment, peer esteem, and dreams of
Nobel prizes remain powerful influences. There are researchers who
will embrace the means to do breakthrough research even if the quid
pro quo for access is relinquishing financial gains from commercial
exploitation.
Similar to PXE, Howard University, a private university with a
historic focus on African-Americans, has announced plans to biobank
with the objective of influencing what research is undertaken-namely
to encourage research on diseases with a distinguishably high incidence
rate among those of African descent. 51 Howard is gathering DNA
samples from 25,000 people, drawing from its global alumnae network
44 See Robert Wells, Intellectual Property/Ownership Interests, 66 LA. L. REv. 69, 73
(2005).
45 See generally NBAC COMMISSIONED PAPERS, supra note 12.
46 See generally Alan E. Guttmacher & Francis S. Collins, Welcome to the Genomic
Era, 349 NEw ENG. J. MED. 996 (2004). See also Noah, supra note 11, at 4-11;
Malinowski, supra note 11, at 231-43.
47 David E. Winickoff, Governing Population Genomics: Law, Bioethics and
Biopolitics, 43 JURIMETRICS J. 187, 223 (2003).
48 PXE International, http://www.pxe.org (providing further information about this
condition and PXE).
49 Winickoff, Biopolitics, supra note 47, at 224.
'0 See id.
51 See Capstone Online, College of Medicine and First Genetic Trust Form Biobank:
Data to Advance Study of Disease Risks Among People of African Descent (June 2,
2003), http://www.howard.edu/newsevents/Capstone/2003/June/news2.htm (last
visited Jan. 14, 2006).
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and patients at hospitals affiliated with its College of Medicine.52
Howard is building this biobank, called the Genomic Research in the
African Diaspora Biobank ("GRAD Biobank"), in collaboration with
First Genetic Trust, a commercial biobanker.53 In addition, biobanking
already has proven a means of entry into the genomics revolution for
the populations of Iceland and Estonia,54 and several other nations are
undertaking biobanking endeavors.55 A number of teaching hospitals
in the U.S. 6 and the State of Utah57 are doing the same.
Methodologies for organizing biobanks tend to be disease-
centered (e.g., PXE 58), nation-centered (e.g., deCode's biobank that
encompasses the vast majority of the population of Iceland5 9), ancestry-
centered (e.g. the International Haplotype Mapping Project ("HMP") or
"HapMap" approach 6), or ethnicity-centered (e.g., Howard
University's effort61). Avoiding explicit use of race in biobanking and
related research may help avoid readily reverting to social and cultural
notions of race. However, these notions are too ingrained to be
removed from popular thought simply by avoiding the terminology, or
even by doing so and shifting to more scientifically sound
methodologies such as ancestry. 62  Consider that popular interest in
52 Alan Pollack, Big DNA Files to Help Blacks Fight Diseases, N.Y, TIMES, May 27,
2003, at Al, A20.
53 First Genetic Trust, http://www.firstgenetic.net.
54 See generally Mylene Deschenes & Clemintine Sallee, Accountability in Population
Biobanking: Comparative Approaches, 33 J.L. MED & ETHICS 40 (2005).
5' See generally id. See also Bartha Maria Knoppers, Biobanking: International
Norms, 33 J.L. MED & ETHICS 7, 7 (2005); Malinowski, supra note 9, at 47-50.
56 Several major hospitals, including Duke University Medical Center, are
collaborating with Ardais Corporation to engage in biobanking. Ardais,
http://www.ardais.comlpartners/partners.shtml. See Michael J. Malinowski,
Technology Transfer in BioBanking: Credits, Debits and Population Health Futures,
33 J. L. MED. & ETHICS 54, 57 (2005); Winickoff, supra note 47, at 207.
57 The State of Utah, in conjunction with the University of Utah and the Huntsman
Cancer Foundation, has formed GenData, a non-profit corporation, to engage in
biobanking that utilizes the rich legacy of medical record keeping associated with
Utah's Mormon community. See BARRY R. FURROW ET AL., HEALTH CARE LAW 22-
23 (2003).
58 See supra notes 47-50 and accompanying text.
59 See deCode, http://www.decode.com (providing more information about the
company). See generally Henry T. Greely, Iceland's Plan for Genomics Research:
Facts and Implications, 40 JURIMETRICS J. 153 (2000).60 See infra notes 75-84 and accompanying text.
61 See supra notes 47, 53-55.
62 Professor Sharona Hoffman has observed that "[s]everal studies reveal that only
half of physical anthropologists and less than one-third of cultural anthropologists
1014 VOL.9.2:1005
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tracing ancestry through DNA among African Americans has been
reported even though only a miniscule percentage of ancestral groups
within the human species have been extensively decoded.63  Social,
cultural, and racial identity based upon historic norms appears to be the
inspiration. 64  Scientific reality is that, especially with a legacy of
migration, tribal integration, war, and conquests, ancestral matching for
any individual is complicated given that contemporary population
genetics is in its infancy and the entire human species has been decoded
only sporadically and at the margins. 65  With only approximately
30,000 genes in the human genome (most expectations until completion
of the map of the human genome reached 100,000+ active genes),66 the
human species is relatively young and genetically homogenous under
present scientific standards, 67 which center largely on gene function.
68
Genetic matches to populations yet to be decoded may prove much
closer than matches to the very limited number of populations already
sampled extensively and added to any particular database established at
this time. In fact, when the human species is comprehensively decoded
genetically, which may take many years, present experience suggests
that categorization based upon genetic commonality may vary
maintain that homo sapiens can be categorized by biological 'races."' Sharona
Hoffman, Is There a Place for "Race" as a Legal Concept?, 36 ARIZ. ST. L.J. 1093,
1123 (2004). She also makes a strong argument for "[d]ismantling the notion of
'race."' Id. at 1159. However, in this author's estimation, removing the terminology
from law alone is unlikely to cause even a meaningful crack in a notion so rooted in
culture and society at least for a generation or two. The same is likely to prove true
even if the notion is disproved by science.
63 See generally Amy Harmon, Blacks Pin Hope on DNA to Fill Slavery's Gaps in
Family Trees, N.Y, TIMES, July 25, 2005, at A1, A17.
64 See generally id.
65 Kenneth Kidd, Tensions in Process and Discovery, Remarks at Louisiana State
University Law Center Symposium: The Genomics Revolution? Science, Law and
Policy (Feb. 6, 2004) (transcript on file with author). See Harmon, supra note 63, at
A17.
66 Alan E. Guttmacher & Francis S. Collins, Genomic Medicine-A Primer, 347 NEW
ENG. J. MED. 1512, 1514 (2002).
67 Human beings share 99.9 percent of these genes meaning that, with whole genes as
the level of measure, variation in the human population is just one tenth of a percent.
Moreover, 90 to 95 percent of this variation appears at equal rates in every human
population. Richard S. Cooper et al., Race and Genomics, 348 NEW ENG. J. MED.
1166, 1167 (2003); Noah A Rosenberg et al, Genetic Structure of Human
Populations, 298 SCIENCE 2381, 2381 (2002).
68 Kidd, supra note 65.
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significantly from cultural and social norms. 69  From a clinical
perspective, this entire exercise may prove much less significant than
understanding how environmental exposures influenced by culture,
social norms, socio-economics, and other factors interact with genetics
to influence human health.7
Fortunately, there is an intense, ongoing debate over the
scientific soundness of race-based research.7' Contrary positions were
presented in the November 2004 issue of Nature Genetics.72 One
position presented is that race has a genetic basis: DNA links people to
geographic continents-regions that correspond with their self-identified
racial classifications, and these populations have distinguishable
genetic characteristics-such as the SCN5A gene carried by one in nine
African Americans that confers a twenty-four-fold increase in sudden
infant death syndrome ("SIDS").73  The counter position is that race
lacks any reliable biological basis and, for meaningful science and
medicine, links between genes and disease must be made directly rather
than through the convoluted path cleared by social and cultural
constructs such as race.74
69 See id. See generally Pilar N. Ossorio, The Concept of Race in Social, Cultural
and Political History, and the Potential Impact of Haplotype Mapping on the Future,
66 LA. L. REV. 131 (2006).
70 See Ossorio, Concept of Race, supra note 69 at 139-140; Richard S. Cooper et al,
Race and Genomics, 348 NEW ENG. J. MED. 1166, 1169 ( 2003); Jonathan Kahn,
Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure
Research, 46 PERSP. BIOLOGY & MED. 473, 480 (2003); Judith B. Kaplan & Trude
Bennett, Use of Race and Ethnicity in Biomedical Publication, 289 JAMA 2709, 2712
(2003); Pamela Sankar et al., Genetic Research and Health Disparities, 291 JAMA
2985, 2987-88.
71 See Hoffman, supra note 62, at 1113-1128. See also David Rotman, Genes,
Medicine, and the New Race Debate, TECH. REV., June 2003, at 41, 48, 50.
72 See Neil Risch et al., Categorization of Humans in Biomedical Research: Genes,
Race, and Disease 3 GENOME BIOLOGY 1, 1 (2002), available at
http://genomebiology.com/content/pdf/gb-2002-3-7-comment2007.pdf.
73 Lynn B. Jorde & Stephen P. Wooding, Genetic Variations, Classifications, and
Race, 28 NATURE GENETICS S28, S28 (2004). See also Esteban Gonzalez Burchard
et al., The Importance of Race and Ethnic Background in Biomedical Research and
Clinical Practice, 348 NEW ENG. J. MED. 1170, 1171 (2003). The SNC5A discovery
was reported in the Journal of Clinical Investigation in February, 2006. See Thomas
H. Maugh II, Gene Raises Chance of SIDS, ADVOCATE, Feb. 2, 2006, at 4A.
Although African American children are three times more likely than Caucasian
children to die from SIDS, the medical significance of this finding is tempered by the
fact that SCN5A appears to count for only five percent of SIDS deaths in African
American children. See id.
74 See id. See also Robert S. Schwartz, Racial Profiling in Medical Research, 344
NEW ENG. J. MED. 1392, 1392 (2001).
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This debate is arguably being developed most effectively
through application associated with the HapMap Project undertaken by
the NIH, National Center for Human Genome Research Institute
(NCHGRI), to explore the methodology of population genetics research
based upon ancestry.75 HMP is a collaboration among scientists and
funding agencies from Japan, the United Kingdom, Canada, China,
Nigeria, and the United States.76 The goal of HMP is to raise the
concept of familial-pedigree studies up to the population level-to
compare the genetic sequences of different individuals to identify
chromosomal regions where genetic variants are shared.77 HMP was
commenced in October 2002, with Stage I planned for completion in
fall 200578 The objective of this first phase of HMP was to analyze
DNA from populations with African, Asian, and European ancestry.
79
Stage I encompassed collection of samples from just 270 people:
Africans (thirty sets of familial samples from the Yoruba people of
Ibadan, Nigeria); Japanese (forty-five unrelated individuals from the
Tokyo area); Chinese (forty-five unrelated individuals from Beijing);
and Europeans (thirty trio samples from European-Mormon families in
the U.S.). 80 The sample selection was based consciously upon ancestry
rather than any direct notions of race. 81  Nevertheless, HMP has
advanced with thoughtful attention to the implications of race-genetics
connections. An ethics committee, co-chaired by Dr. Bartha Knoppers
and Dr. Ellen Wright Clayton, has vested tremendous effort to address
implications and develop algorithms for population genetics that
82potentially carry far beyond HMP. Professors Knoppers and Clayton
also have made significant individual contributions by emphasizing at
71 See HapMap Project, http://www.hapmap.org. See National Human Genome
Research Institute, http://www.genome.gov. See generally, Ellen Wright Clayton,
Implications for Existing Law/Regulations, 66 LA. L. REv. 125 (2006); Ossorio, supra
note 70, at 131.
76 See About the HapMap, http://www.hapmap.org/thehapmap.html.en.
17 See id. See also Clayton, supra note 75, at 127; Ossorio, supra note 70, at 132-33.
78 HapMap Project, http://www.hapmap.org.
79 See generally Genomics Revolution, supra note 8; HapMap Project,
http://www.hapmap.org.
80 See generally HapMap Project, http://www.hapmap.org. See also Ossorio, supra
note 70, at 131-142.
81 See generally HapMap Project, http://www.hapmap.org. See also HapMap Sample
Populations, http://www.hapmap.org/hapmappopulations.html.en.
82 See Guidelines for Referring to the HapMap Populations in Publications and
Presentations, http://www.hapmap.org/citinghapmap.html.en. See also How Are
Ethical Issues Being Addressed?, http://www.hapmap.org/ethicalconcems.html.en
(discussing ethics issues involving the HapMap Project).
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conferences and in print that HMP is a pilot program to probe the
scientific validity of ancestry-based population genetics. 83  A
fundamental outcome of this application of population genetics is
pragmatic identification of ethical, legal, social and other policy
implications of the research, and pragmatic methodologies and
algorithms sensitive to those implications have been developed.
84
With all of the primary biobanking methodologies, including
biobanking centered on diseases relatively more prevalent in
populations identified as racial groups by popular cultural and social
notions of race, there is a real possibility-arguably, a likelihood for
the foreseeable future-of encouraging race-based medicine and race-
based research in contemporary genomics. 85  Genetic science has
proven a powerful influence, and this influence is destined to expand
with advancement of the field of genomics. 86 As discussed above, IOM
and AHRQ data on treatment disparities suggest that race-based
medicine is a present reality. 87  The data indicate that race-based
medicine is being practiced with influences other than good science and
to the relative detriment of non-whites. 88 Moreover, there already are
instances of race-based medicine where genomics is used to the
detriment of non-white populations-for example, use of three loci,
HLA A, B and D, for matching in renal transplants. 89 However, there
also are documented instances where race-based medicine is being
reported to improve outcomes to the benefit of HCHNs-most notably,
the FDA's recent approval of BiDil among African Americans to
prevent death from heart disease by lowering salt retention, and
SCN5A screening to identify children with heightened risk of SIDS.90
In addition, as summarized by Professor Hoffman,
83 See generally Clayton, supra note 75.
84 See generally id.; Ossorio, supra note 70.
85 See id. at 139-41.
86 See generally DOROTHY NELKIN & SUSAN LINDEE, THE DNA MYSTQUE: THE GENE
As A CULTURAL ICON (1995); Sharona Hoffman, supra note 62; Michael J.
Malinowski, Choosing the Genetic Makeup of Our Children: Our Eugenics Past-
Present, and Future?, 36 CONN. L. REV. 125 (2003).87 See supra notes 25-33 and accompanying text.
88 See id.
89 C. Thomas Caskey, Haplotype Mapping and Its Applications, Remarks at Louisiana
State University Law Center Symposium: The Genomics Revolution? Science, Law
and Policy (Feb. 6, 2004) (transcript on file with author).90 See supra note 73 and accompanying text (discussion of SCN5A); FDA Advisory
Committee Recommends BiDil to Treat Black Patients with HF, CARDIOVASCULAR
DRUG NEWS, June 17, 2005; John Pope, Heart Drug Study Triggers Questions-Test
Results Promising for African Americans, TIMES-PICAYUNE, Nov. 16, 2004, at Al. It
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Today it is believed that members of different populations
have higher susceptibilities to different diseases and
respond differently to certain treatments. For example,
"racial" differences have been demonstrated with respect to
diabetes complications, and researchers have detected
genetic differences among "racial" groups that relate to
HIV, Crohn's disease, and Alzheimer's disease. In
addition, one controversial study found that black patients
with chronic heart failure did not respond well to a
commonly used drug, leading some doctors to stop
providing the medication to African-American patients.
9
'
Many ongoing biobanking efforts are driven by HCHNs who,
perhaps in conjunction with the goal of commercial returns, hope to
build a basic science floor of inclusion for their bank populations that
may spill over into medical outcomes favoring their populations. Even
if the science proves disappointing and these clinical applications are
not realized, third-party use of these biobanks and resulting revenues
and IP rights introduce resources and a possibility to improve the health
care of the donor populations. Examples already discussed include
biobanking by Howard University,92 deCode,93 and Estonia.94 The
return could be direct or through arrangements that grant HCHN-
related research institutions access to biobank users' enabling
technologies, or perhaps even a collaborative role in the research itself.
For national biobankers in developing economies, a possible quid pro
quo for access might be the establishment of a domestic research
facility. Another possibility is construction of manufacturing facilities,
is important to note that challenges have been raised to the biological soundness of
this FDA's BiDil decision in light of the temptation of sponsors to manipulate clinical
data to obtain even limited market entry and, subsequently, realize much broader
markets through off-label use. See Pope, supra, at Al. See generally Jonathan Kahn,
How A Drug Becomes "Ethnic": Law, Commerce, and the Production of Racial
Categories in Medicine, 4 YALE J. HEALTH POL'Y, L. & ETHics 1 (2005). The data
also may have been influenced by the study's focus on a type of heart disease that
happens to be prevalent in African Americans because of life style choices. See id.
9' Hoffman, supra note 62, at 1119-1120. As suggested above, such medically
meaningful associations with groups defined by cultural and social norms may prove
more attributable to the interaction of genetics and environmental factors such as diet,
socioeconomic background, and living conditions than genetic ancestry. See supra
note 70 and accompanying text.
92 See supra note 47 and accompanying text.
93 See supra note 92 and accompanying text.
94 See supra note 59 and accompanying text.
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perhaps with incentives from entities such as the World Bank, with the
capacity to at least satisfy domestic use of resulting commercial
products on an at-cost basis and an obligation to do so-albeit with
pharmaceutical sponsor oversight and host government assurances of
full product accountability and recognition of IP rights. On the most
pragmatic level, revenue could be generated and channeled into public
health basics like vaccines, clean water, and sanitation.
Admittedly, questions about the enforceability of any such
arrangement over time invite skepticism and pessimism. However, a
number of recent events and circumstances suggest at least an
environment of opportunity and the possibility of a break between the
present/future and the past. These include fuller implementation of the
Trade Related Intellectual Property Sections ("TRIPS") of the General
Agreement on Tariffs and Trade ("GATT"); 95 extensive global
familiarity with technology transfer and development and government-
industry-academia collaborations in the life sciences; the strengthening
of international institutions such as the World Trade Organization,
World Bank, and World Health Organization; and international
pressures on pharmaceutical companies and governments to close the
life science crevasse between developed and developing economies-
all underscored by global epidemiological crises such as the threat of an
avian flu pandemic as this article goes into print, and controversies
such as access to AIDS drugs in African nations.
96
Where there is commercial life science demand, there is
opportunity. 97 This is a lesson made vividly clear by the university
experience over the last fifteen years. With access to samples and
medical information now at a premium and rising in value, HCHNs that
engage in biobanking and apply technology transfer and development
norms will have opportunities to access and reap benefits from the
genomics revolution.99 There are developed models, algorithms, and
guidelines to draw from to undertake such biobanking, including some
that address ethical, legal, and social implications in the complicated
global setting. 98  Again, this is a major HMP contribution, and the
HMP application of population genetics encompasses working
95 Agreement on Trade Related Aspects of Intellectual Property Rights, Apr. 15,
1994, Marrakesh Agreement Establishing the World Trade Organization, Annex IC,
Legal Instruments-Results of the Uruguay Round, 33 I.L.M. 81 (1994).
96 See generally JEFFREY SACHS, THE END OF POVERTY: ECONOMIC POSSIBILITIES FOR
OUR TIME (2005).
97 See Malinowski, supra note 9, at 51.
99 See generally id.
98 See generally id.
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knowledge of many other biobanking case studies-Iceland, Estonia,
and so forth-and international guidelines and norms. 99 For example,
the United Nations Educational, Scientific and Cultural Organization
("UNESCO") has issued an International Declaration on Human
Genetic Data,'00 the Council for International Organizations of Medical
Sciences ("CIOMS") has put forth ethical guidelines for biomedical
research, 101 and the World Health Organization ("WHO") has
compiled a report on genetic databases. 102 Some academics also are
providing thoughtful insights and guidance. For example, Professor
Knoppers recently framed the global challenge of approaching
biobanking with primarily public health norms rather than primarily
with human subject norms that emphasize the rights of the
individual. 0 3 An additional challenge is to expand the conceptual
scope of public health beyond the traditional disease continuum-
prevention to treatment-to encompass R&D. 104
However, assuming such global biobanking by HCHNs is even
achievable at this time, a fundamental question lingers: Would
embracing the opportunity to engage in biobanking other than from a
general population, disease-centered methodology inevitably reinforce
notions of race-based genetics and medicine? The path to reaching
comprehensive science will be incremental, and probably will include
some confirmations of those notions, especially until a critical mass of
population genetics is achieved. Although we are not genetically
diverse relative to most other species, 105 our species has been impactedgenetically through ancestry. Significant genotype-phenotype
99 See generally Knoppers, supra note 55, at 7-14.
'OO UNITED NATIONS EDUCATIONAL, SCIENTIFIC AND CULTURAL ORGANIZATION
(UNESCO), INTERNATIONAL DECLARATION ON HUMAN GENETIC DATA (2003),
available at
portal.unesco.org/en/ ... &URLDO=DOTOPIC&URLSECTION=201 .html.
'o' COUNCIL FOR INTERNATIONAL ORGANIZATION OF MEDICAL SCIENCES (CIOMS),
INTERNATIONAL ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOLVING
HUMAN SUBJECTS (2002), available at
http://www.cioms.ch/frame-guidelinesnov_2002.htm.
102 WORLD HEALTH ORGANIZATION (WHO), GENETIC DATABASES-ASSESSING THE
BENEFITS AND THE IMPACT ON HUMAN RIGHTS AND PATIENT RIGHTS (2003),
available at http://www.law.ed.ac.uk/ahrb/publications/online/whofinalreport.rtf.
103 See generally Knoppers, supra note 55. As pointed out by Professor Parmet, the
very nature of public health is population health. WENDY E. PARMET, Introduction:
The Interdependency of Law and Public Health, in LAW IN PUBLIC HEALTH PRACTICE
xxvi (Richard A. Goodman et al. eds., 2003)
104 PUBLIC HEALTH LAW AND ETHICS: A READER 4 (Lawrence 0. Gostin ed., 2002)
'05 See supra note 67 and accompanying text.
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connections have been identified by working in ethnically-defined
populations, such as the association of BRCA-1 mutations and a form
of breast cancer through a study focused on Ashkenazi Jewish women
and the identification of the gene that causes Huntington's disease by
studying an isolated population with an extremely high incident rate of
the disease.10 6  Where groups are being studied, scientists are
identifying genetic subtleties that impact human health.
0 7
Nevertheless, if the present majority opinion in the biological science
community proves true, advancing genomics research through
population genetics ultimately will disprove many long-held notions of
race and culture.l°8 Present science suggests no broad genetic reality
to notions of race, especially in the absence of environmental
influences. 10 9 Still, those notions are deeply rooted and, even when
challenged by meaningful science, they are likely to linger. Aggressive
biobanking, in addition to advancing the genomics revolution and
introducing opportunities for HCHNs to participate, is likely to quicken
confrontation of social-cultural notions of race through science in a
comprehensive and definitive manner.
CONCLUSION
The U.S. has a legacy of disparity in access for minorities in both
human health research and medicine, and that legacy lingers on.' 
°
Now, contemporary science in the form of the genomics revolution,
which has centered on population genetics and bioinformatics,''' is
forcing answers to one of societies' most controversial questions: Is
there genetic reality to historic notions of race? Given that confronting
this question is inevitable, the scientific and social agenda should be to
move genomics forward in a responsible manner-to push through the
present state of population genetics uncertainty into broadly meaningful
genomics medicine, and to include more HCHNs along the way.
Responsible biobanking is a means to advance these ambitious
objectives, and it should be embraced accordingly.
106 See generally Sandra Soo-Jin Lee et al., The Meaning of "Race" in the New
Genomics: Implications for Health Disparities Research, 1 YALE J. HEALTH POL'Y,
L. & ETHICS 33 (2001).
107 See, e.g., supra note 73.
108 See generally Kidd, supra note 65.
109 See id; cf supra note 74.
"~o See supra notes 18-41 and accompanying text.
1 1 See supra notes 11-12, 43-47 and accompanying text.
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